NCT06330077
Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis treatment 2 not_yet_recruiting NCT05084638
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. treatment 4 active_not_recruiting NCT05705986
Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS) No drug interventions Not Available Not Available recruiting NCT02038049
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis treatment 2 terminated NCT01704183
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00203112
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline treatment 2 completed NCT00203099
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine treatment 2 completed NCT04857489
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis No drug interventions Not Available Not Available unknown_status NCT00202982
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose treatment 2 completed NCT04705610
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography No drug interventions other Not Available completed NCT01848327
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis No drug interventions treatment Not Available completed NCT02361697
DTI in Children With Multiple Sclerosis No drug interventions diagnostic Not Available unknown_status NCT01080053
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) No drug interventions Not Available Not Available completed NCT00859482
Differential Immune Effects of Natalizumab No drug interventions Not Available Not Available completed NCT01080040
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients No drug interventions Not Available Not Available completed NCT02247310
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon Not Available Not Available completed NCT01080027
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) Not Available Not Available completed NCT02638038
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years treatment 2 completed NCT05090371
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation treatment 4 recruiting NCT05949580
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis No drug interventions Not Available Not Available not_yet_recruiting NCT06083753
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis No drug interventions treatment 2 recruiting NCT06586177
Understanding the 'durable Effect' Concept of B-cell Modulating Therapies No drug interventions Not Available Not Available recruiting NCT04602390
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis No drug interventions treatment 1 completed NCT05123703
A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis treatment 3 recruiting NCT02696590
High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients No drug interventions treatment Not Available completed NCT02647502
A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis No drug interventions treatment Not Available completed NCT02549703
Mitochondrial Dysfunction and Disease Progression No drug interventions Not Available Not Available completed NCT02266121
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis No drug interventions treatment Not Available terminated NCT01925690
Development of a Motivational Intervention to Improve Treatment Adherence in MS No drug interventions health_services_research Not Available completed NCT01717664
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) No drug interventions treatment 2 completed NCT01067521
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo treatment 3 completed NCT00390221
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT00367484
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis treatment 4 completed NCT00203021
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness treatment 4 completed NCT06526000
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies No drug interventions Not Available Not Available completed NCT06395909
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis No drug interventions Not Available Not Available completed NCT05351411
Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis No drug interventions Not Available Not Available completed NCT04925778
Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate Not Available Not Available withdrawn NCT04858763
MS Relapses During COVID-19 Pandemic No drug interventions Not Available Not Available unknown_status NCT04604041
Investigation of Subclinical Markers of Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT04289909
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) No drug interventions other Not Available unknown_status NCT04997148
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS) No drug interventions Not Available Not Available completed NCT04201470
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis No drug interventions other Not Available completed NCT04047628
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) treatment 3 recruiting NCT04032171
Study of Evobrutinib in Participants With RMS treatment 3 terminated NCT03783416
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis No drug interventions other 1 recruiting NCT03594487
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis No drug interventions treatment 1 active_not_recruiting NCT03562975
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Not Available Not Available active_not_recruiting NCT03536559
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis treatment 2 terminated NCT05446285
Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE No drug interventions Not Available Not Available unknown_status NCT05755061
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis No drug interventions treatment 1 active_not_recruiting NCT03157830
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab No drug interventions Not Available Not Available completed NCT03093324
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 treatment 3 completed NCT04578639
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease treatment 3 active_not_recruiting NCT02753088
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis treatment 3 completed NCT02428218
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 3 withdrawn NCT02306811
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 treatment 2 terminated NCT02310048
Comparative Oral Bioavailability Study of MT-1303 No drug interventions treatment 1 completed NCT02283853
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) treatment 3 active_not_recruiting NCT02364986
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis treatment 1 unknown_status NCT02222948
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis treatment 2 terminated NCT02142205
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) treatment 4 completed NCT02076841
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen No drug interventions Not Available Not Available completed NCT01963611
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) treatment 2 terminated NCT01808885
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. treatment 1 completed NCT01805336
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality No drug interventions other Not Available completed NCT01755871
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis treatment 4 terminated NCT01742052
Dose-finding Study of MT-1303 No drug interventions treatment 2 completed NCT01706107
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants No drug interventions Not Available Not Available terminated NCT01498887
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy treatment 4 completed NCT01407211
Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient No drug interventions treatment 4 unknown_status NCT01307332
Advanced MRI Measures of Repair in Alemtuzumab Treated Patients treatment 3 completed NCT01244139
Safety Study of BIIB033 in Subjects With Multiple Sclerosis Not Available 1 completed NCT01257958
Vitamin D Pilot Study in Patients With Multiple Sclerosis treatment 1 completed NCT01142518
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone Not Available Not Available completed NCT01156311
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis treatment 2 completed NCT01144052
Natalizumab De-escalation With Interferon Beta-1b treatment 4 completed NCT01111656
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b treatment 2 completed NCT01071083
Treatment Interruption of Natalizumab treatment 2 completed NCT01051817
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler treatment 2 completed NCT01051349
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis treatment 2 completed NCT01040117
Sensori-motor Integration Training in Multiple Sclerosis No drug interventions treatment 0 completed NCT01037907
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) No drug interventions treatment 2 terminated NCT00947752
Safety of New Formulation of Glatiramer Acetate treatment 3 completed NCT00914758
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) No drug interventions Not Available Not Available unknown_status NCT00902135
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) Not Available Not Available completed NCT00835770
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) treatment 3 completed NCT00882999
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 2 completed NCT00837785
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS basic_science 1 completed NCT00641537
CLARITY Extension Study treatment 3 completed NCT00623415
Flupirtine as Oral Treatment in Multiple Sclerosis treatment 2 terminated NCT00493298
Tysabri Observational Program Not Available Not Available completed NCT00493116
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta treatment 4 completed NCT00391352
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Not Available Not Available completed NCT00360906
Omega-3 Fatty Acid Treatment in Multiple Sclerosis treatment 2 / 3 completed NCT00245622
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis No drug interventions treatment 2 completed NCT00211887
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx treatment 3 completed NCT00220493
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients educational_counseling_training 1 unknown_status NCT00203047
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate treatment 4 terminated NCT05181215
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects treatment 1 completed NCT05978531
Observational Study of Persistence on Bafiertam Treatment In Routine Clinical Practice Not Available Not Available enrolling_by_invitation NCT05706220
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis No drug interventions Not Available Not Available enrolling_by_invitation NCT05171972
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment Not Available Not Available active_not_recruiting NCT04971005
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial treatment 2 terminated NCT04832399
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants Not Available Not Available completed NCT06435962
Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple No drug interventions Not Available Not Available not_yet_recruiting NCT04570670
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects treatment 1 completed NCT03758820
Behavior Cognitive Therapy on Fatigue Impact in MS Patients No drug interventions supportive_care Not Available completed NCT04468165
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region Not Available Not Available completed NCT04225312
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis treatment 4 enrolling_by_invitation NCT04009005
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis No drug interventions treatment Not Available active_not_recruiting NCT03539094
Intermittent Fasting in Multiple Sclerosis No drug interventions treatment Not Available completed NCT04688788
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis treatment 3 active_not_recruiting NCT03718247
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS No drug interventions Not Available Not Available completed NCT03193866
COMparison Between All immunoTherapies for Multiple Sclerosis. Not Available Not Available unknown_status NCT05604092
Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS No drug interventions Not Available Not Available completed NCT06282081
Serum Neurofilament Light in Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT03381170
An Extension of the TG1101-RMS201 Trial treatment 2 completed NCT03177083
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy treatment 4 completed NCT03302442
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT03284970
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes No drug interventions Not Available Not Available completed NCT03091569
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy No drug interventions supportive_care 4 completed NCT02833714
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. No drug interventions Not Available Not Available terminated NCT03004079
Clinical Importance of Glucose Regulation in Relapsing MS No drug interventions Not Available Not Available unknown_status NCT03000647
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis No drug interventions treatment Not Available completed NCT02823951
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® Not Available Not Available completed NCT02975349
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis treatment 2 terminated NCT02720107
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) basic_science 4 completed NCT02677077
Clinical Disease Activity With Long Term Natalizumab Treatment Not Available Not Available completed NCT02323269
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) Not Available Not Available terminated NCT02325440
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya treatment 4 unknown_status NCT02495766
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis treatment 1 / 2 completed NCT02255656
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 treatment 4 completed NCT02277964
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod No drug interventions Not Available Not Available completed NCT02373098
Fingolimod Effect on Cytokine and Chemokine Levels treatment 4 completed NCT02205489
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA treatment 4 completed NCT02159573
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) Not Available Not Available completed NCT02104492
Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis No drug interventions treatment Not Available unknown_status NCT02090413
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis treatment 4 completed NCT02010554
Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS No drug interventions health_services_research Not Available completed NCT01945359
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design No drug interventions Not Available Not Available completed NCT01975298
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) treatment 3 withdrawn NCT01943526
Ireland Natalizumab (TYSABRI) Observational Program Not Available Not Available completed NCT01874145
Safety and Tolerability of Glatiramer Acetate treatment 3 completed NCT01890655
Extension Study of MT-1303 No drug interventions treatment 2 completed NCT01838668
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) treatment 3 completed NCT01790269
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod No drug interventions Not Available Not Available terminated NCT01701856
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis treatment 4 terminated NCT01705457
Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis treatment 4 unknown_status NCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis treatment 2 withdrawn NCT01578785
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 3 terminated NCT01564511
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis No drug interventions treatment Not Available completed NCT01534182
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) treatment 4 completed NCT01490502
Vitamin D Supplementation in Multiple Sclerosis treatment 3 completed NCT01466114
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition treatment 2 unknown_status NCT01485003
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants Not Available Not Available completed NCT01464905
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) treatment 3 unknown_status NCT01436643
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression treatment 4 terminated NCT01405820
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) treatment 2 completed NCT01428726
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis No drug interventions treatment 2 completed NCT01285401
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment treatment 2 completed NCT01225289
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients No drug interventions treatment 4 completed NCT01185821
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis treatment 2 completed NCT01142453
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients Not Available Not Available completed NCT01142492
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) Not Available Not Available completed NCT01064401
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis treatment 3 completed NCT01058005
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis Not Available 3 terminated NCT01044576
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00939549
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis treatment 2 withdrawn NCT00884481
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS No drug interventions Not Available Not Available completed NCT00870740
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT00818038
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function Not Available Not Available completed NCT00771043
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a treatment 4 withdrawn NCT00745615
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease treatment 2 terminated NCT00616187
Atorvastatin in Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT00668343
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo treatment 3 completed NCT00645749
Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis No drug interventions treatment 1 completed NCT00594087
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) treatment Not Available completed NCT00559702
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) treatment 1 completed NCT00534261
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? treatment 4 completed NCT00525668
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) treatment 1 / 2 completed NCT00492466
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies treatment 4 completed NCT00492570
GER-009-06-AVX Early Therapy in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00451204
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) treatment 2 completed NCT00451451
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis treatment 3 completed NCT00420212
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis treatment 3 completed NCT00429442
Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis treatment 3 withdrawn NCT00398528
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis Not Available Not Available terminated NCT00349193
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod treatment 2 completed NCT00315367
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties treatment 4 completed NCT00337779
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). treatment 3 completed NCT00297232
Natalizumab (Tysabri) Re-Initiation of Dosing treatment 3 terminated NCT00289978
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis treatment 3 completed NCT00242268
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis treatment 3 unknown_status NCT00232193
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS No drug interventions Not Available Not Available completed NCT00219908
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis Not Available 2 terminated NCT00239655
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) No drug interventions treatment 2 terminated NCT00202995
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS prevention 4 terminated NCT00200655
Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis treatment 3 completed NCT00168766
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS treatment 4 completed NCT00101959
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects treatment 4 withdrawn NCT00078338
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis treatment 4 completed NCT01842191
Efficacy of Fish Oil in Multiple Sclerosis No drug interventions treatment 4 completed NCT06159712
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis No drug interventions basic_science Not Available recruiting NCT05277740
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT04940065
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen No drug interventions Not Available Not Available active_not_recruiting NCT04711148
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis treatment 2 active_not_recruiting NCT04530318
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis No drug interventions treatment 2 recruiting NCT04115930
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients No drug interventions Not Available Not Available completed NCT03825601
PET With [18F]Flumazenil as an Index of Neurodegeneration in MS No drug interventions diagnostic Not Available unknown_status NCT04032158
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) treatment 3 terminated NCT03498131
Melatonin in Patients With Multiple Sclerosis (MS). treatment 0 completed NCT05327322
Functional Outcomes From Diets in Multiple Sclerosis No drug interventions other Not Available recruiting NCT05758831
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. treatment 3 recruiting NCT05906992
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis treatment 3 recruiting NCT05423769
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt Not Available Not Available completed NCT03471338
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme No drug interventions other Not Available active_not_recruiting NCT03464448
Mechanistic Studies of Teriflunomide in RRMS Not Available Not Available completed NCT03345940
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis treatment 4 terminated NCT03244696
Behavior and Activity Monitoring in MS No drug interventions treatment Not Available completed NCT02490982
Teriflunomide Observational Effectiveness Study Not Available Not Available completed NCT02424396
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis No drug interventions treatment 2 completed NCT02472938
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis treatment 4 withdrawn NCT02258217
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) other Not Available completed NCT02293967
Mass Balance Study of MT-1303 No drug interventions treatment 1 completed NCT02335892
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod No drug interventions Not Available Not Available completed NCT02342704
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants treatment 4 terminated NCT02217982
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation treatment 4 terminated NCT02193217
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 Not Available 1 completed NCT02125604
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany treatment 4 completed NCT02090348
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate treatment 4 withdrawn NCT01917019
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis treatment 3 completed NCT01930708
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes treatment 4 completed NCT01884935
PK and PD Study of Natalizumab in Pediatric Subjects With RRMS treatment 1 completed NCT01797965
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 treatment 3 terminated NCT01767701
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis treatment 2 completed NCT01709812
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS No drug interventions treatment 4 withdrawn NCT01623596
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. treatment 4 completed NCT01541618
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT01538355
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis No drug interventions treatment Not Available completed NCT01456416
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities No drug interventions Not Available Not Available completed NCT01450124
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) No drug interventions treatment 2 completed NCT01462318
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis other 3 completed NCT01417273
Impact of Vitamin A on Multiple Sclerosis (MS) treatment 4 unknown_status NCT01416155
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT01317004
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change treatment 4 completed NCT01337427
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis treatment 3 withdrawn NCT01310166
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis basic_science 4 completed NCT01097668
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis No drug interventions treatment 1 completed NCT00919217
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms No drug interventions Not Available Not Available recruiting NCT00917839
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis treatment 2 unknown_status NCT00869986
A Study for Patients With Relapsing Remitting Multiple Sclerosis treatment 2 / 3 completed NCT00879658
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis treatment 2 completed NCT00813969
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS No drug interventions treatment 1 completed NCT00574041
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose treatment 4 terminated NCT00382629
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis No drug interventions treatment 2 completed NCT00317941
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif treatment 4 completed NCT00288626
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study treatment 2 completed NCT00210301
Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS treatment Not Available unknown_status NCT00203086
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00203073
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. diagnostic 2 completed NCT02305264
Imaging of Intracerebral Inflammation in MS diagnostic Not Available completed NCT04567264
Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis No drug interventions treatment Not Available completed NCT06526364
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) No drug interventions Not Available Not Available not_yet_recruiting NCT04121221
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS No drug interventions treatment 3 completed NCT04528121
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis No drug interventions treatment Not Available completed NCT00099502
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients treatment 3 completed NCT05168384
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis No drug interventions treatment 1 / 2 recruiting NCT00984984
Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses treatment 3 unknown_status NCT06381297
Speech in Noise Discrimination Skills in Multiple Sclerosis Patients. No drug interventions diagnostic Not Available completed NCT06276634
Intermittent Hypoxia in Persons With Multiple Sclerosis No drug interventions treatment Not Available recruiting NCT04756687
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera Not Available Not Available completed NCT01108887
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. No drug interventions Not Available Not Available completed NCT02633033
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse No drug interventions Not Available Not Available completed NCT01141751
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy No drug interventions Not Available Not Available completed NCT01591551
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness supportive_care 4 completed NCT05359653
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy treatment 1 / 2 recruiting NCT04625153
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial treatment 2 recruiting NCT05663853
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients No drug interventions Not Available Not Available completed NCT05519553
Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis No drug interventions other Not Available not_yet_recruiting NCT00292253
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects No drug interventions treatment 3 completed NCT04768777
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis No drug interventions supportive_care Not Available not_yet_recruiting NCT04048577
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab treatment 4 unknown_status NCT04448977
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI Not Available Not Available recruiting NCT00888277
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects No drug interventions Not Available Not Available completed NCT03535298
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS treatment 4 active_not_recruiting NCT00228397
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis treatment 2 completed NCT06567197
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands No drug interventions Not Available Not Available recruiting NCT01142583
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00675883
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS No drug interventions Not Available Not Available completed NCT03872583
Understanding Magnetic Resonance Imaging in Multiple Sclerosis No drug interventions other Not Available completed NCT05296161
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis treatment 4 recruiting NCT06495593
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis other 4 not_yet_recruiting NCT01435993
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis treatment 1 terminated NCT00050778
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT04458688
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT05345288
Effect of Computerized Cognitive Training in Persons With MS No drug interventions treatment Not Available completed NCT04261556
tDCS to Enhance Cognitive Training in Multiple Sclerosis No drug interventions treatment Not Available withdrawn NCT02637856
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) treatment 3 completed NCT03385356
Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis treatment 4 completed NCT03979456
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS treatment 3 active_not_recruiting NCT03653585
Cortical Lesions in Patients With Multiple Sclerosis No drug interventions Not Available Not Available completed NCT04042415
Calorie Restriction in Multiple Sclerosis No drug interventions treatment Not Available active_not_recruiting NCT02587715
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS No drug interventions treatment 1 / 2 unknown_status NCT00676715
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT01628315
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study No drug interventions Not Available Not Available completed NCT02903537
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) treatment 1 recruiting NCT01431937
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers treatment 1 completed NCT03060759
Light Therapy as Treatment for Fatigue in Multiple Sclerosis No drug interventions treatment Not Available completed NCT03963375
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis basic_science 4 active_not_recruiting NCT02403570
Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis No drug interventions Not Available Not Available completed NCT01772199
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis treatment 2 completed NCT02901106
Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate treatment 4 terminated NCT02587806
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS No drug interventions treatment 1 / 2 unknown_status NCT06129019
the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis No drug interventions supportive_care Not Available recruiting NCT01143441
Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) No drug interventions treatment 1 completed NCT02275741
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis Not Available Not Available completed NCT00276341
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis treatment 3 completed NCT01414634
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells No drug interventions treatment 1 / 2 completed NCT05684016
Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM No drug interventions diagnostic Not Available completed NCT00461396
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron Not Available Not Available completed NCT06516458
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT00213135
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) treatment 3 completed NCT01416363
Healthy Volunteer Study Using 3 Different Formulations of Firategrast treatment 1 completed NCT05532163
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 4 terminated NCT04655222
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program Not Available Not Available completed NCT02418325
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS No drug interventions treatment 1 / 2 terminated NCT05752630
Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT06390930
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS No drug interventions treatment Not Available not_yet_recruiting NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy No drug interventions treatment 1 recruiting NCT02137707
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya Not Available Not Available completed NCT01518660
Multiple Sclerosis and Progressive Resistance Training No drug interventions treatment Not Available completed NCT01201343
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients treatment 4 completed NCT02369926
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis No drug interventions health_services_research 2 unknown_status NCT00292266
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) treatment 3 completed NCT02525874
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). treatment 3 completed NCT05605782
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety No drug interventions Not Available Not Available active_not_recruiting NCT01808482
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) No drug interventions treatment 1 terminated NCT05335031
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) No drug interventions Not Available Not Available active_not_recruiting NCT00097331
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis treatment 2 completed NCT04565431
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI Not Available Not Available recruiting NCT01134627
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] treatment 2 terminated NCT02280876
Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) treatment 1 / 2 completed NCT02427776
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis No drug interventions treatment 1 / 2 terminated NCT03126760
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) treatment 4 terminated NCT03239860
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis treatment 2 terminated NCT02471560
Tecfidera and the Gut Microbiota other 4 completed NCT04221191
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP Not Available Not Available completed NCT01424462
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. treatment 1 completed NCT03205280
Clinical Decision Support System (CADIMS) for MS Diagnostic No drug interventions Not Available Not Available completed NCT04972929
Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis No drug interventions treatment Not Available recruiting NCT05964829
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis No drug interventions treatment Not Available active_not_recruiting NCT00235989
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis treatment 2 completed NCT01909492
Measurement of Relaxin Peptide in Multiple Sclerosis (MS) No drug interventions Not Available Not Available completed NCT00306592
Natalizumab Re-Initiation of Dosing treatment 3 completed NCT04073940
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis No drug interventions other Not Available unknown_status NCT02769767
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis. No drug interventions Not Available Not Available unknown_status NCT01080001
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina No drug interventions Not Available Not Available completed NCT05658601
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) No drug interventions Not Available Not Available recruiting NCT02315872
ACTH for Fatigue in Multiple Sclerosis Patients treatment 3 completed NCT06389968
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis No drug interventions basic_science Not Available not_yet_recruiting NCT01453868
The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis No drug interventions health_services_research 0 unknown_status NCT03497468
Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis No drug interventions treatment Not Available unknown_status NCT05417269
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study treatment 1 / 2 active_not_recruiting NCT01417312
Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients No drug interventions basic_science Not Available completed NCT03085810
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) treatment 3 completed NCT05958381
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation No drug interventions treatment 1 / 2 recruiting NCT02579681
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 treatment 3 completed NCT04580381
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort Not Available Not Available completed NCT02515695
Phase I BP Interferon (IFN) Beta-001 treatment 1 completed NCT02861014
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) treatment 3 completed NCT01420055
Fingolimod -Response According to Coping - Evaluation treatment 4 completed NCT05834855
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS treatment 3 recruiting NCT02019550
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use No drug interventions treatment 4 completed NCT00411723
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis treatment 1 unknown_status NCT03342638
Maximizing Outcome of Multiple Sclerosis Transplantation treatment 3 terminated NCT00441103
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis treatment 3 completed NCT04261790
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis treatment 4 active_not_recruiting NCT02914964
Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study No drug interventions treatment Not Available active_not_recruiting NCT01470521
Worms for Immune Regulation of Multiple Sclerosis treatment 2 completed NCT03561402
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) Not Available Not Available completed NCT06413602
The Synergistic Effects of AIH and FES in Persons With MS No drug interventions treatment Not Available not_yet_recruiting NCT04280484
Acute Intermittent Hypoxia in Persons With Multiple Sclerosis No drug interventions treatment Not Available completed NCT03401879
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis No drug interventions basic_science Not Available unknown_status NCT00220779
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis treatment 2 completed NCT05615454
Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis No drug interventions treatment Not Available recruiting NCT02506751
Open-label Study of Liothyronine in MS treatment 1 completed NCT00930553
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab treatment 3 completed NCT03958877
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis treatment 3 active_not_recruiting NCT00242177
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability treatment 1 completed NCT04880577
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis treatment 2 withdrawn NCT01112345
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters No drug interventions Not Available Not Available completed NCT02040298
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis treatment 2 completed NCT00548405
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two treatment 3 completed NCT03283397
A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS No drug interventions treatment 3 terminated NCT05007483
Efficacy of Diet on Quality of Life in Multiple Sclerosis No drug interventions supportive_care Not Available recruiting NCT01158183
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis No drug interventions Not Available Not Available completed NCT02423083
Oral Guanabenz for Multiple Sclerosis treatment 1 terminated NCT03500328
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial No drug interventions treatment Not Available recruiting NCT05265728
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis treatment 3 terminated NCT04260711
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). treatment Not Available unknown_status NCT01110993
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) No drug interventions Not Available Not Available completed NCT05438693
Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt No drug interventions Not Available Not Available completed NCT06095271
MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC No drug interventions other Not Available recruiting NCT02419378
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential basic_science 4 completed NCT02517788
Phase I BP Interferon (IFN) Beta-004 treatment 1 completed NCT05290688
Cellular microRNA Signatures in Multiple Sclerosis No drug interventions basic_science Not Available not_yet_recruiting NCT05340985
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis No drug interventions basic_science 4 unknown_status NCT02555215
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) treatment 3 completed NCT04121637
To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis. No drug interventions treatment Not Available unknown_status NCT03942952
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. No drug interventions Not Available Not Available completed NCT00027300
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis treatment 3 completed NCT02410200
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS treatment 2 completed NCT06195800
Biomarkers of aHSCT No drug interventions Not Available Not Available recruiting NCT06408259
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis treatment 3 not_yet_recruiting NCT05204459
MS-ResearchBiomarkerS No drug interventions Not Available Not Available recruiting NCT05080270
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis No drug interventions treatment 0 completed NCT04233970
Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis No drug interventions supportive_care Not Available completed NCT03347370
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis Not Available Not Available completed NCT05482542
Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis treatment Not Available withdrawn NCT05029206
Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden No drug interventions Not Available Not Available completed NCT03679806
Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis No drug interventions treatment Not Available completed NCT02493049
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 2 completed NCT05366036
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis No drug interventions Not Available Not Available completed NCT02675413
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS basic_science 4 withdrawn NCT03975413
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT01941004
Safety and Efficacy of Fingolimod in MS Patients in China treatment 3 withdrawn NCT05920018
Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis No drug interventions treatment Not Available recruiting NCT02687919
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis No drug interventions treatment Not Available completed NCT05218317
Evaluation of Relapse Presence in Multiple Sclerosis No drug interventions Not Available Not Available completed NCT05510817
Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS No drug interventions other Not Available recruiting NCT05028634
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy treatment 3 completed NCT04002934
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis treatment 2 recruiting NCT00076934
Safety of RG2077 in Patients With Multiple Sclerosis treatment 1 completed NCT00112034
AVONEX® Combination Trial - "ACT" Not Available 4 completed NCT06303024
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis No drug interventions treatment Not Available recruiting NCT02064816
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis treatment 4 completed NCT01667796
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health No drug interventions other Not Available completed NCT02782858
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS treatment 2 completed NCT06325358
the EXPOSITION Study No drug interventions Not Available Not Available not_yet_recruiting NCT03870763
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants treatment 3 terminated NCT03610139
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients No drug interventions other Not Available unknown_status NCT02744222
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis treatment 2 / 3 completed NCT01466322
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. treatment 1 completed NCT04450030
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis Not Available Not Available unknown_status NCT00530348
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One treatment 3 completed NCT03768648
Cognition and MRI Markers in MS Patients With Aubagio® Treatment No drug interventions diagnostic Not Available completed NCT05019248
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine No drug interventions Not Available Not Available unknown_status NCT00206648
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS treatment 4 completed NCT06345157
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients Not Available Not Available not_yet_recruiting NCT03718026
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis No drug interventions Not Available Not Available completed NCT00030966
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis treatment 3 completed NCT03691766
Photobiomodulation Therapy in Persons With Multiple Sclerosis No drug interventions supportive_care Not Available completed NCT01142466
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone treatment 4 completed NCT04993274
Sensitivity of Motor Assessment in MS - a Prospective Cohort Study No drug interventions Not Available Not Available unknown_status NCT00595920
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis No drug interventions treatment 2 terminated NCT02394782
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) No drug interventions Not Available Not Available terminated NCT04833673
The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial No drug interventions supportive_care Not Available completed NCT00067327
Treatment of Multiple Sclerosis Using Over the Counter Inosine treatment 2 completed NCT01116427
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis treatment 2 completed NCT01279876
Melatonin in Relapsing-Remitting Multiple Sclerosis Patients treatment 2 completed NCT00097760
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis treatment 2 completed NCT04885894
An Examination of Cognitive Fatigue Using Functional Neuroimaging Not Available Not Available recruiting NCT01071694
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea Not Available Not Available withdrawn NCT02652091
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction Not Available Not Available completed NCT00587691
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis No drug interventions treatment 1 / 2 completed NCT01075880
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® Not Available Not Available completed NCT05902429
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients treatment 4 active_not_recruiting NCT05648292
The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT04236544
Patient Experiences of Multiple Sclerosis (PExMS) No drug interventions supportive_care Not Available not_yet_recruiting NCT02746744
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. treatment 3 completed NCT04211740
Phase II Clinical Trial of OCH-NCNP1 No drug interventions treatment 2 completed NCT00459667
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose treatment 3 completed NCT02598167
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition No drug interventions Not Available Not Available completed NCT02988401
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis treatment 1 / 2 completed NCT01392872
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant No drug interventions Not Available Not Available completed NCT03689972
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration treatment 3 completed NCT02545868
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis supportive_care 3 completed NCT02461069
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis basic_science 4 completed NCT02580669
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis No drug interventions diagnostic Not Available terminated NCT03387046
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) treatment 2 terminated NCT05496881
Exercise Effects in Multiple Sclerosis No drug interventions supportive_care Not Available recruiting NCT06127095
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments No drug interventions Not Available Not Available recruiting NCT04220814
Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis No drug interventions other Not Available active_not_recruiting NCT00780455
Rehabilitation Study in MS Patients treatment 4 terminated NCT06569550
Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis No drug interventions treatment Not Available not_yet_recruiting NCT04979650
Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis treatment 2 unknown_status NCT05201638
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis treatment 3 recruiting NCT03910738
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis treatment 2 recruiting NCT00071838
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis treatment 2 completed NCT03133403
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy treatment 2 / 3 recruiting NCT02418351
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS No drug interventions treatment 1 / 2 terminated NCT01738347
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). No drug interventions other 1 completed NCT02568111
Brimonidine Tartrate for the Treatment of Injection Related Erythema supportive_care 4 withdrawn NCT06430671
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis No drug interventions treatment 1 / 2 recruiting NCT02587065
Plegridy Satisfaction Study in Participants treatment 4 completed NCT05304520
A Study for Tysabri Participant Preference Not Available Not Available completed NCT05245344
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study No drug interventions Not Available Not Available unknown_status NCT04115488
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® No drug interventions treatment 3 completed NCT03846219
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) treatment 2 active_not_recruiting NCT05811416
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants No drug interventions Not Available Not Available recruiting NCT05172466
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab No drug interventions other Not Available withdrawn NCT02881567
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab treatment 3 terminated NCT01633112
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone treatment 3 terminated NCT05177523
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT01705236
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® basic_science 4 completed NCT01235455
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors Not Available Not Available completed NCT00428584
RNF and Betaseron® Tolerability Study treatment 3 completed NCT05242133
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis treatment 3 completed NCT01125475
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects No drug interventions Not Available Not Available completed NCT00787657
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment Not Available Not Available completed NCT00871780
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients treatment 4 completed NCT01499667
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod treatment 3 terminated NCT02035514
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis No drug interventions treatment 1 / 2 completed NCT01233245
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program Not Available Not Available completed NCT01804647
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease No drug interventions Not Available Not Available completed NCT02686788
TMP001 in Relapsing-remitting Multiple Sclerosis No drug interventions treatment 2 completed NCT06611280
Deuterium Metabolic Imaging in People with Multiple Sclerosis No drug interventions Not Available Not Available not_yet_recruiting NCT00095329
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor treatment 1 / 2 terminated NCT03101735
Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece Not Available Not Available completed NCT02907281
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis No drug interventions Not Available Not Available completed